- Free Shipping On Orders Over 100€
- 30-Day Money Back Guarantee
- Organic & Third Party Tested
- Shop
From Field To Product
Organically grown hemp. Carefully extracted.
- About Us
About Endoca
Our Story
From humble beginnings to a global mission – we grow, harvest, and craft hemp with care for people and planet.
What Is CBD?
CBD is nature’s way to restore balance, calm, and overall well-being – naturally and without the high.
The Process
From seed to shelf, we grow organically, extract cleanly, and follow strict quality standards for purity.
Lab Testing
Every batch is third-party tested to ensure purity, safety, and the exact amount of CBD every time.
Our Values
Sustainability, transparency, and wellness guide every decision – for you and for the planet.
At a glance
Two different origins
Cannabis produces one precursor, CBGA. Three enzymes compete for it, generating the acid forms of THC, CBD and CBC. CBG is the decarboxylated form of whatever CBGA the plant did not convert. In most cultivars that is very little, which is why CBG raw material is expensive.
CBN is not part of that pathway at all. There is no CBNA synthase. CBN forms when THC sits in contact with oxygen, heat and light and its terpene ring aromatises. Aged material has elevated CBN because its THC has degraded. Heating produces it as well: one 2022 analysis found 17.2 percent of delta-9 THC degrading in a gas chromatograph inlet and generating CBN.
The practical consequence is worth stating. CBG content reflects cultivar and harvest timing. CBN content reflects age and heat exposure. One is a cultivation decision, the other a storage outcome.
Mechanism
CBG’s headline finding is alpha-2 adrenoceptor agonism at an EC50 of 0.2 nanomolar, reported in a 2010 paper in the British Journal of Pharmacology using mouse brain membranes. That is the receptor family clonidine acts upon clinically. The same paper found the effect much weaker in isolated tissue than in the binding assay, so the physiological relevance is unresolved. CBG is also a 5-HT1A antagonist. At cannabinoid receptors it is weak.
CBN’s notable finding concerns its metabolite rather than itself. CBN is a low-efficacy CB1 partial agonist, roughly 29 percent maximum effect against THC’s 72 percent. But 11-hydroxy-CBN reaches equivalent brain concentrations and is a CB1 agonist with THC-comparable potency and efficacy. That is the likely route for any central effect, and also why CBN can be weakly intoxicating at very high oral doses.
The evidence
Neither has published human pharmacokinetics, so all dosing guidance for either is extrapolation.
What people get wrong
Legal status and safety
No health claim for CBG, CBN or any cannabinoid is authorised under Regulation (EC) No 1924/2006, and Article 10(3) excludes non-specific wellbeing language. Regulation (EU) No 1169/2011 prohibits attributing disease-related properties to food.
This matters particularly for the focus and sleep positioning these two compounds usually carry. Category names, product names, imagery and testimonials are all treated as claims by enforcement authorities across member states.
Both fall within the EU Novel Food Catalogue entry covering cannabinoid-containing extracts of Cannabis sativa L., and neither is authorised.
CBN carries an additional question. Because concentrated CBN is usually produced by converting THC rather than by extracting naturally occurring material, its status is arguable under national narcotics rules as well as novel food law. Sweden’s treatment of THC-containing extracts is relevant here, as is the Netherlands’ zero-tolerance Opium Act position.
EFSA’s February 2026 provisional safe level applies to CBD isolate of at least 98 percent purity. No equivalent assessment covers CBG or CBN.
How Endoca tests for this
Both appear on every Endoca batch certificate. We report CBN honestly even when it is low, because a low figure indicates material that was extracted and stored properly. In our view a CBN number is quality information before it is anything else.
Frequently asked questions
CBG’s single trial met its objectives. CBN’s single trial did not meet its primary endpoint.
CBG is not. CBN is weakly so at very high doses, through its metabolite.
They are frequently combined and no interaction problem is documented. No study has tested the combination.
Because no cannabinoid health claim is authorised in the EU, and general wellbeing language is excluded as well.
References
Cascio MG et al. Br J Pharmacol 2010;159:129-141.
Cuttler C et al. Sci Rep 2024;14:16163.
Lavender I et al. J Sleep Res 2026;35:e70284.
Arnold JC et al. Neuropsychopharmacology 2025;50:586-595.
Garcia-Valverde MT et al. Front Chem 2022;10:1038729.
EFSA Journal 2026;24:9862.
Last reviewed 1 September 2026.
Educational information about published research and European regulation. Not a health claim.